Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
This guide addresses a reigning industry dilemma: though GLP-1 costs are declining, demand continues to rise
Designed to complement your GLP-1 journey
Resistance training, adequate protein intake, sleep, and nutrition are not optional additions to GLP-1 therapy
This article mainly reviews the anti-atherosclerotic effect of GLP-1 in clinical applications
Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status
